Welcome to our dedicated page for ANI PHARMACEUTICALS SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANI PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANI PHARMACEUTICALS's regulatory disclosures and financial reporting.
ANI Pharmaceuticals insider transaction: Thomas Rowland, SVP, Head - Established Brands, reported sale of 4,975 shares of ANI Pharmaceuticals, Inc. common stock on 08/12/2025 at a weighted average price of $85.71 per share. After the reported sale, the filing shows 40,794 shares beneficially owned.
The filing notes that 304 of those shares were acquired under the company's Employee Stock Purchase Plan and were exempt under Rule 16b-3. The Form 4 was submitted and signed by attorney-in-fact Meredith W. Cook on behalf of Thomas Rowland.
ANI Pharmaceuticals insider transaction: The company's President & CEO and director, Nikhil Lalwani, reported selling 56,960 shares of ANI Pharmaceuticals, Inc. (ANIP) on 08/12/2025 at a weighted average sale price of $85.93 per share. After the sale, he beneficially owns 411,219 shares, reported as directly owned.
The Form 4 was signed by attorney-in-fact Meredith W. Cook on 08/14/2025 and notes the shares were sold in multiple trades with execution prices ranging from $84.40 to $87.47. No derivative transactions or other securities classes are reported.
Ori Gutwerg, listed as SVP, Generics at ANI Pharmaceuticals (ANIP), reported a sale of 5,873 shares of ANI common stock on 08/12/2025. The shares were sold in multiple trades at prices ranging from $86.50 to $86.79, with a disclosed weighted average sale price of $86.53. After the transactions, the reporting person beneficially owned 84,024 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact for the reporting person.
Meredith W. Cook, Sr. VP, General Counsel & Sec. of ANI Pharmaceuticals (ANIP), reported the sale of 400 shares of the company’s common stock on 08/13/2025 at a price of $88.87 per share. After the sale, Ms. Cook beneficially owns 76,474 shares directly. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on September 17, 2024, indicating the transaction followed a prearranged instruction to sell. The Form 4 shows a single non-derivative disposition and lists Ms. Cook’s role and contact address with the issuer.
ANI Pharmaceuticals Inc reports that SVP & CFO Stephen P. Carey exercised stock options for 50,000 shares of common stock at $46.4900 per share on August 12, 2025, then sold 50,000 shares at $86.0700 per share the same day. He continues to hold 180,863 common shares directly.
Thomas Haughey, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 19,341 shares of the company's common stock on 08/12/2025 at a weighted-average price of $85.93 per share, according to this Form 4 filing. After the sale, Haughey beneficially owned 36,521 shares. The filing indicates the shares were sold in multiple trades at prices ranging from $84.50 to $87.16, and the form was signed by attorney-in-fact Meredith W. Cook on 08/14/2025.
The report is a standard Section 16 disclosure showing an insider disposition; it provides the exact quantities, price range, and resulting beneficial ownership recorded on the form.
ANI Pharmaceuticals (ANIP) notice reports a proposed sale of 47,010 shares of common stock via Merrill Lynch on 08/14/2025 with an aggregate market value of $4,206,603.82. The shares represent part of the outstanding share count of 21,688,772. The filer states the shares were acquired on 11/19/2021 in a company buyout from ANI Pharmaceuticals and that the payment is a compensatory payment. No sales by the filer are reported in the prior three months. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
ANI Pharmaceuticals, Inc. (ANIP) filed a Form 144 notifying a proposed sale of 56,960 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $4,894,823.42. The form lists the approximate date of sale as 08/12/2025 and reports 21,688,772 shares outstanding for the issuer.
The securities to be sold were acquired as restricted stock from the issuer on four dates in 2025: 02/14 (12,333 shares), 02/28 (11,666), 03/07 (16,292), and 03/23 (16,669), which total the 56,960 shares listed for sale. The filing also states "Nothing to Report" for securities sold during the past three months and includes the standard signer representation that they do not possess undisclosed material adverse information. Certain filer identification and contact fields in the filing appear blank in the provided content.
ANI Pharmaceuticals (ANIP) has a Form 144 notice showing an insider proposes to sell 19,341 common shares, representing the full amount of two restricted stock grants received on 03/23/2022 (9,292 shares) and 04/27/2023 (10,049 shares). The planned sale is listed with an aggregate market value of $1,662,047.56 and an approximate sale date of 08/12/2025 on NASDAQ.
The shares to be sold compare with 21,699,636 shares outstanding, or roughly 0.09% of outstanding stock, and the filer reports no securities sold in the past three months. The filer also certifies they do not possess undisclosed material adverse information about the issuer.
ANI Pharmaceuticals (ANIP) filed a Form 144 notifying a proposed Rule 144 sale of 50,000 common shares to be handled by Morgan Stanley Smith Barney LLC on 08/12/2025 on the NASDAQ. The filing lists an aggregate market value of $4,303,590.00 and 21,699,636 shares outstanding, making the proposed sale roughly 0.23% of outstanding shares and implying an approximate price of $86.07 per share. The shares were reported as acquired the same day by stock option exercise from the issuer with cash payment. The filing reports no securities sold in the past three months. The extract does not include the filer identity or a dated signature in the provided content.